Improvement programs and VAD program M2 alternatin

e707004304 · Wysłany: Nie 23:24, 27 Mar 2011

Improvement programs and VAD program M2 alternating treatment of multiple myeloma clinical observation of 27 cases

To support rapid recovery after treatment; another 2 patients after the use of vincristine was a sense of abdominal distension, and there is numbness of the limbs, the symptomatic treatment can be tolerated. None of this group died due to side effects of chemotherapy. * 698.3 MM patients to discuss abnormal proliferation of malignant plasma cells produce M protein, bone and soft tissue infiltration, clinical manifestations of bone destruction, bone pain, pathologic fractures, anemia, and hypercalcemia. Renal insufficiency, the high age of onset and natural course of disease for 6-12 months. As improvements in chemotherapy, interferon, the use of thalidomide, particularly the launching of hematopoietic stem cell transplantation, MM The response rate has been significantly improved. MP program recognized nearly 30 years the standard treatment of MM programs, the effective rate was 53.2% of its population, median survival of patients is 24-36 months. Although this program effective, but results were not satisfactory. In recent years, with autologous peripheral blood stem cell transplantation, allogeneic hematopoietic stem cell transplantation in MM patients with progressive, MP program as the standard treatment of MM has been challenged the status of the program. Since the majority of MM patients were older, and coupled with economic conditions, this stage is not likely to stem cell transplantation as a routine treatment, most patients treatment is chemotherapeutic regimens. Clinicians, the diagnosis and treatment of MM in the selection of appropriate treatment programs for patients with prolonged disease-free survival, overall survival and quality of life, reduce treatment costs are very important. Jiang Medical discount of 26 meters 2004 No. 9 M2 program improved the patients with VAD, alternatively, costs less,[link widoczny dla zalogowanych], no significant increase in infection rate and no serious side effects, 9 patients survived more than 5 years, 3 cases 9 years I have been living good effect in this group may be the first program with the modified M2 MM's condition to get some control, and then used interchangeably with the VAD program reduced M2 tumor cells to chemotherapy improved the incidence of drug resistance, and the VAD program by slow intravenous drip, can maintain an effective intracellular drug concentration of drug and tumor cells extended contact time, help to improve anti-tumor effect. M2 is recommended improvement programs and VAD program used interchangeably as the first choice for treatment of MM. 4